Pipeline

We are building a deep pipeline of potentially differentiated therapies, with the goal of advancing care and outcomes for patients with diverse inflammatory diseases

  • Preclinical
  • Phase I
  • Phase II 
  • Pivotal or Phase III*

CBP-201

Antibody targeting IL-4Rα cytokine receptor
(Th2 cell modulator)

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Atopic Dermatitis (AD)
  •  
  •  
  •  
  •  
  •  
Atopic Dermatitis (AD)
Asthma
  •  
  •  
  •  
  •  
  •  
Asthma

CBP-307

Small molecule targeting S1P1
(Th1 cell modulator)

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Ulcerative Colitis (UC)
  •  
  •  
  •  
  •  
  •  
Ulcerative Colitis (UC)
Crohn's Disease (CD) **
  •  
  •  
  •  
  •  
  •  
Crohn's Disease (CD) **

CBP-174

Peripherally restricted
H3 receptor antagonist

  • Preclin
  • Ph 1
  • Ph 2
  • Ph 3
Pruritus Associated with AD
  •  
  •  
  •  
  •  
  •  
Pruritus Assoc.
with AD

*The Company’s clinical trial in China of CBP-201 in patients with AD is included as the Company intends to submit a New Drug Application in China based on the results of this trial, pending pre-NDA discussions with the Chinese Center for Drug Evaluation of the National Medical Products Administration.

**Phase 2 CD trial ended early due to COVID-19-related enrollment challenges.

  • Key:
  • Ongoing
  • Planned
Don't delete this section - it contains the styling for the pipeline bars, but is invisible to visitors